Form 4: BeOne Medicines GC Sells Shares After Option Exercise

BeOne Medicines' SVP and General Counsel, Lee Chan Henry, exercised stock options and subsequently sold American Depositary Shares under a pre-arranged trading plan.

Summary

• SVP, General Counsel Lee Chan Henry engaged in transactions on January 7, 2026.
• Acquired a total of 664 American Depositary Shares (ADSs) through derivative security conversions/exercises (M transaction code) at prices ranging from $159.03 to $213.32 per ADS.
• Immediately sold all 664 ADSs at a price of $331.76 per ADS, pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
• Separately, exercised options to acquire 2,626 Ordinary Shares at an exercise price of $14.96, 3,458 Ordinary Shares at $16.41, and 2,548 Ordinary Shares at $12.23.
• Retains direct beneficial ownership of 223,106 Ordinary Shares and 245,583 Ordinary Shares underlying derivative options after these transactions.

Sentiment

Score: 6

Explanation: While an insider sale can be seen negatively, the fact that it's part of a pre-planned 10b5-1 program mitigates concerns. The exercise of options also shows the insider is monetizing vested equity.

Positives

• Management exercising options indicates confidence in the company's long-term value, even if some shares are sold.
• The sale was pre-planned under a Rule 10b5-1 plan, suggesting it is not a reaction to new negative information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the sale as a lack of confidence, though the 10b5-1 plan mitigates this. The exercise of options increases the float slightly.

Key Dates

Recommendation

The insider transaction, involving both option exercises and a pre-planned sale, is a routine event for executives managing their equity compensation. The sale under a 10b5-1 plan suggests a pre-determined financial planning decision rather than a reaction to new company-specific information. While any insider sale warrants attention, this particular transaction does not present new information that would fundamentally alter the investment thesis for BeOne Medicines. Investors should continue to hold based on the company's underlying fundamentals rather than this specific insider transaction.

Keywords

BeOne Medicines, ONC, Form 4, insider trading, stock options, share sale, Lee Chan Henry, General Counsel, 10b5-1 plan, American Depositary Shares, Ordinary Shares